

F. No. 31015/14/2017-Pricing
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(Pricing Section)

Shastri Bhawan, New Delhi – 110 001

Dated December 2025

Order

In partial modification of this Department's Order of even number dated 30.11.2017 read with the Corrigendum of even number dated 10.1.2018 (hereinafter collectively referred to as the said Order), the Central Government hereby includes an additional member on the Committee of Experts formed *vide* the said Order under paragraphs 11(4) and 15(1) of the Drugs (Prices Control) Order, 2013, for making recommendations under paragraphs 5(2)(i), 11(4), 15(1) and 15(3) *ibid.*, by inserting in paragraph 2 of the said Order, below clause (iv), the following clause, namely:—

“(v) Representative (Expert) from the Health Technology Assessment of India (HTAI) under the Department of Health Research — Member.”

2. A copy of the said Order dated 30.11.2017 and Corrigendum dated 10.1.2018 is attached for ready reference.
3. This issues with the approval of the Minister in charge.

(Khayl Leishangam)
Joint Director (Pricing)

Copy to:

1. All committee members
2. Chairman, National Pharmaceutical Pricing Authority
3. Member Secretary, Health Technology Assessment of India
4. PS to Minister in charge of the Ministry of Chemicals and Fertilizers
5. PS to Minister of State for Chemicals and Fertilizers
6. PPS to Secretary, Department of Pharmaceuticals
7. Head of Division, Department of Pharmaceuticals Informatics Division, for uploading this Order on the Department's website
8. Guard file

95

F.No.31015/14/2017-Pricing(pt)
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
(Pricing Section)

Room No. 340B, A-Wing, Shastri Bhawan,
New Delhi, dated the 10.01.2018

Corrigendum

Sub:- Constitution of a Committee of Experts - regarding

The following amendment is made in para 2(i) of this Department's Order no. 31015/14/2017-Pricing dated 30/11/2017 on the above mentioned subject:-

"para 2(i)

For

**Member Secretary, National Pharmaceutical Pricing Authority (NPPA)-
Convener;**

Read

Advisor (Cost), National Pharmaceutical Pricing Authority (NPPA)- Convener;"

2. The other contents of the above said order dated 30/11/2017 shall remain unchanged.
3. This issues with the approval of Competent Authority.

Sudhansh Pant

(Sudhansh Pant) 10/1
Joint Secretary

Department of Pharmaceuticals
7C

Copy to:-

1. Secretary, Department of Health Research/DG, ICMR, IIInd Floor, IRCS Building, 1, Red Cross Road, New Delhi - 110003.
2. Chairman, NPPA, 3rd/5th Floor, YMCA Cultural Centre Building, 1, Jai Singh Road, New Delhi.
3. Dr. G.N. Singh, Drugs Controller General (India), Ministry of Health & Family Welfare, FDA Bhawan, ITO, Kotla Road, New Delhi.
4. Joint Secretary (NIPER) – Department of Pharmaceuticals.

Copy for information to:-

- (i) PS to Minister (Chemicals & Fertilizers)
- (ii) PS to Minister of State (Chemicals & Fertilizers)
- (iii) PSO to Secretary, Department of Pharmaceuticals.
- (iv) Director (NIC) with the request to upload the same on Department's website, Facebook and Twitter Handle.

copy
11/11/18

2

F.No.31015/14/2017-Pricing
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
(Pricing Section)

Room No. 340B, A-Wing, Shastri Bhawan,
New Delhi, dated the 30.11.2017

Order

Sub:- Constitution of a Committee of Experts - regarding

In view of the experience gained from implementation of Drugs (Prices Control) Order, 2013 (DPCO, 2013), it has been decided to constitute a single multi-disciplinary "Committee of Experts" by the Government as envisaged by two different nomenclature i.e. Standing Committee of Experts under para 5(2) (i) & para 15(1) and the Committee of Experts under para 11(4) to discharge the functions under DPCO, 2013 for consultation on all technical issues related to pricing, launch of new drugs along with other ancillary provisions where more clarity may be required, and opine on matters referred to it by the National Pharmaceutical Pricing Authority (NPPA) in discharge of its functions.

2. The **Committee of Experts shall comprise of the following members:-**


- (i) Member Secretary, National Pharmaceutical Pricing Authority (NPPA)- **Convener**;
- (ii) Representative (Scientist/Expert) from Central Drugs Standard Control Organization (CDSCO) (Subject matter expert) not below the rank of Dy. DCGI - **Member**;
- (iii) Representative (Scientist/Expert) from the Department of Health Research (DHR)/Indian Council of Medical Research (ICMR) (Subject matter expert) not below the rank of Deputy Secretary or equivalent - **Member**;
- (iv) Representative (Pharmacoeconomics expert) from NIPER (to be nominated by DoP). - **Member**;

3. The above said Committee would be empowered to invite or co-opt any other specialist (like Medical Devices) depending on exigencies of the circumstances requiring resolution of any specific matter arising out of implementation of various provisions of DPCO, 2013, as and when it may be required.

4. The Terms of Reference (TOR) of the Committee shall be as under:-

- (a) To deliberate and recommend its opinion on the claims of pharma companies about additional therapeutic features associated with any formulation including in terms of Para 11 (3) of DPCO, 2013 and recommending separate ceiling price of scheduled formulations or retail price of a new drug with specified therapeutic rationale, considering the type of packaging or pack size or dosage compliance or content in the pack namely liquid, gaseous or any other form, in the unit dosage as the case may be, conforming to Indian Pharmacopeia or other standards as specified in the Drugs and Cosmetics Act, 1940 (23 of 1940) and the rules made thereunder for the same formulation;
- (b) To deliberate, interpret and recommend its opinion on the claims of pharma companies about additional Pharmacoeconomics features associated with any formulation/API including in terms of Para 15 (1) of DPCO, 2013;

- (c) To deliberate, interpret and recommend its opinion on the technical related issues whether the drug is scheduled or non-scheduled on the basis of ingredients used in the formulation;
- (d) To deliberate, interpret and recommend its opinion on the claims of pharma companies about novelty associated with indigenous R&D content passed through the development process of relevant API/formulation; and recommend exemption from the application of provisions of para 32 of DPCO, 2013 for a period of five years.
- (e) To discuss any other issue referred to the Committee of Experts concerning technical matters involved in disposing of any issue raised by any stakeholder.
5. NPPA shall decide and refer the relevant issues within 4 weeks of receiving the applications, to the Committee for its opinion.
6. The Committee shall submit its report with its findings and opinion in each case within a period of 4 weeks.
7. The recommendations of this committee shall be considered by the NPPA which shall pass a reasoned order within 4 weeks from receiving the recommendations of the Committee, deciding the issue(s) in hand finally.
8. This issues with the approval of Hon'ble Minister (C&F).


(Sudhansh Pant) 30/11/2017
Joint Secretary
Department of Pharmaceuticals

Copy to:-

1. Secretary, Department of Health Research/DG, ICMR, Nirman Bhawan, New Delhi - with the request to nominate an expert to represent your Department.
2. Chairman, NPPA, 3rd/5th Floor, YMCA Cultural Centre Building, 1, Jai Singh Road, New Delhi.
3. Dr. G.N. Singh, Drugs Controller General (India), Ministry of Health & Family Welfare, FDA Bhawan, ITO, Kotla Road, New Delhi - with the request to nominate an expert to represent your organisation.
4. Joint Secretary (NIPER) - with the request to nominate a Pharmacoeconomics expert as representative of DoP from NIPER.

Copy for information to:-

- (i) PS to Minister (Chemicals & Fertilizers)
- (ii) PS to Minister of State (Chemicals & Fertilizers)
- (iii) Secretary, Department of Pharmaceuticals.